Penicillamine chemical structure
Find information on thousands of medical conditions and prescription drugs.

Cuprimine

Penicillamine is a pharmaceutical of the chelator class. It is sold under the trade names of Cuprimine and Depen. The pharmaceutical form is D-penicillamine, as L-penicillamine is toxic (it inhibits the action of pyridoxine). It is a metabolite of penicillin, although it has no antibiotic properties. more...

Home
Diseases
Medicines
A
B
C
Cabergoline
Caduet
Cafergot
Caffeine
Calan
Calciparine
Calcitonin
Calcitriol
Calcium folinate
Campath
Camptosar
Camptosar
Cancidas
Candesartan
Cannabinol
Capecitabine
Capoten
Captohexal
Captopril
Carbachol
Carbadox
Carbamazepine
Carbatrol
Carbenicillin
Carbidopa
Carbimazole
Carboplatin
Cardinorm
Cardiolite
Cardizem
Cardura
Carfentanil
Carisoprodol
Carnitine
Carvedilol
Casodex
Cataflam
Catapres
Cathine
Cathinone
Caverject
Ceclor
Cefacetrile
Cefaclor
Cefaclor
Cefadroxil
Cefazolin
Cefepime
Cefixime
Cefotan
Cefotaxime
Cefotetan
Cefpodoxime
Cefprozil
Ceftazidime
Ceftriaxone
Ceftriaxone
Cefuroxime
Cefuroxime
Cefzil
Celebrex
Celexa
Cellcept
Cephalexin
Cerebyx
Cerivastatin
Cerumenex
Cetirizine
Cetrimide
Chenodeoxycholic acid
Chloralose
Chlorambucil
Chloramphenicol
Chlordiazepoxide
Chlorhexidine
Chloropyramine
Chloroquine
Chloroxylenol
Chlorphenamine
Chlorpromazine
Chlorpropamide
Chlorprothixene
Chlortalidone
Chlortetracycline
Cholac
Cholybar
Choriogonadotropin alfa
Chorionic gonadotropin
Chymotrypsin
Cialis
Ciclopirox
Cicloral
Ciclosporin
Cidofovir
Ciglitazone
Cilastatin
Cilostazol
Cimehexal
Cimetidine
Cinchophen
Cinnarizine
Cipro
Ciprofloxacin
Cisapride
Cisplatin
Citalopram
Citicoline
Cladribine
Clamoxyquine
Clarinex
Clarithromycin
Claritin
Clavulanic acid
Clemastine
Clenbuterol
Climara
Clindamycin
Clioquinol
Clobazam
Clobetasol
Clofazimine
Clomhexal
Clomid
Clomifene
Clomipramine
Clonazepam
Clonidine
Clopidogrel
Clotrimazole
Cloxacillin
Clozapine
Clozaril
Cocarboxylase
Cogentin
Colistin
Colyte
Combivent
Commit
Compazine
Concerta
Copaxone
Cordarone
Coreg
Corgard
Corticotropin
Cortisone
Cotinine
Cotrim
Coumadin
Cozaar
Crestor
Crospovidone
Cuprimine
Cyanocobalamin
Cyclessa
Cyclizine
Cyclobenzaprine
Cyclopentolate
Cyclophosphamide
Cyclopropane
Cylert
Cyproterone
Cystagon
Cysteine
Cytarabine
Cytotec
Cytovene
Isotretinoin
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Uses

Penicillamine is used as a form of immunosuppression to treat rheumatoid arthritis. It works by reducing numbers of T-lymphocytes, inhibiting macrophage function, decreasing IL-1, decreasing rheumatoid factor, and preventing collagen from cross-linking.

It is used as a chelating agent:

  • In Wilson's disease, a rare genetic disorder of copper metabolism, penicillamine treatment relies on its binding to accumulated copper and elimination through urine.
  • In cystinuria, a hereditary disorder featuring increased cystine excretion, penicillamine binds with the cystine to make it more soluble.

History

Dr John Walshe (1956) first described the use of penicillamine in Wilson's disease. He had discovered the compound in the urine of patients (including himself) who had taken penicillin, and experimentally confirmed that it increased urinary copper excretion by chelation. He had initial difficulty convincing several world experts of the time (Drs Denny Brown and Cumings) of its efficacy, as they held that Wilson's disease was not primarily a problem of copper homeostasis but of amino acid metabolism, and that dimercaprol should be used as a chelator. Later studies confirmed both the copper-centered theory and the efficacy of D-penicillamine. Walshe also pioneered other chelators in Wilson's such as triethylene tetramine 2HCl and tetrathiomolybdate (Walshe 2003).

Read more at Wikipedia.org


[List your site here Free!]


American Academy of Pediatrics issues treatment guidelines for lead exposure in children
From American Family Physician, 9/1/95

The Committee on Drugs of the American Academy of Pediatrics (AAP) has reviewed the current therapy for lead intoxication and issued guidelines for the treatment of lead exposure in children. The statement includes a review of available chelating agents and recommendations for their use. The complete statement appears in the July 1995 issue of Pediatrics.

Introduction

There are currently two parenteral and two oral agents used for the chelation of lead. These include dimercaprol (Bal in Oil); calcium disodium ethylenediaminetetraacetic acid (Calcium Disodium Versenate), also known as calcium EDTA; succimer (Chemet), and penicillamine (Cuprimine, Depen). Penicillamine is not approved for use in the treatment of lead poisoning.

The following recommendations have been excerpted from the AFP statement.

Recommendations

* Chelation treatment is not indicated in patients with blood lead levels of less than 25 [micro]g per dL. In these patients, environmental intervention is necessary.

* Patients with blood lead levels of 25 to 45 [micro]g per dL need aggressive environmental intervention but should not routinely receive chelation therapy, because there is no evidence that chelation avoids or reverses neurotoxicity. If blood lead levels stay in this range despite repeated environmental study and abatement, some patients may benefit from (oral) chelation therapy by enhanced lead excretion.

* Chelation therapy is indicated in patients with blood lead levels between 45 and 70 [micro]g per dL. In the absence of clinical symptoms suggesting encephalopathy (e.g., obtundation, headache and persistent vomiting), patients may be treated with succimer at 30 mg per kg per day for five days, followed by 20 mg per kg per day for 14 days. To monitor for adverse effects and to begin environmental abatement, children may need to be hospitalized for the initiation of their therapy. Children should not be discharged from the hospital until their environment has been made safe. An alternate regimen would be to use calcium EDTA as inpatient therapy (25 mg per kg per day for five days). Before chelation with either agent is started, if an abdominal radiograph shows that enteral lead is present, bowel decontamination may be considered as an adjunct to treatment.

* Patients with blood lead levels of greater than 70 [micro]g per dL or with clinical symptoms suggesting encephalopathy require inpatient chelation therapy using the most effective parenteral agents available. Lead encephalopathy is a life-threatening emergency that should be treated using contemporary standards for intensive care treatment of increased intracranial pressure, including appropriate pressure monitoring, osmotic therapy and drug therapy in addition to chelation therapy. Therapy is initiated with intramuscular dimercaprol at 25 mg per kg per day, divided into six doses. The second dose of dimercaprol is given four hours later, followed immediately by intravenous calcium EDTA at 50 mg per kg per day as a single dose, infused during several hours or as a continuous infusion. Current labeling of calcium EDTA does not support the intravenous route of administration, but clinical experience suggests that it is safe and more appropriate in children. The hemodynamic stability of these patients, as well as changes in neurologic status that may herald encephalopathy, needs to be closely monitored. Patients must be adequately hydrated to ensure renal excretion.

Therapy for all of the recommendations needs to be continued for a minimum of 72 hours. After this initial treatment, two alternatives are possible: (1) parenteral therapy with two drugs (calcium EDTA and dimercaprol) may be continued for a total of five days or (2) therapy with calcium EDTA alone may be continued for a total of five days. If dimercaprol and calcium EDTA are used for the full five days, a minimum of two days with no treatment should elapse before considering another five-day course. Before therapy is changed in patients with lead encephalopathy, parenteral chelation should be continued with both drugs until they are clinically stable.

After chelation therapy, a period of reequilibration of 10 to 14 days should be allowed before another blood lead level is obtained.

COPYRIGHT 1995 American Academy of Family Physicians
COPYRIGHT 2004 Gale Group

Return to Cuprimine
Home Contact Resources Exchange Links ebay